Published online before print January 27, 2003, doi: 10.1161/01.CIR.0000048192.52098.DD
(Circulation. 2003;107:896.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction
From Inotek Pharmaceuticals Corp, Beverly, Mass (P.P., P.B., J.G.M., L.V., A.D., E.S., C.S.); the Critical Care Division, Department of Internal Medicine, University Hospital, Lausanne, Switzerland (L.L.); the Department of Physiology, New York Medical College, Valhalla (P.M.K., Z.U., M.S.W.); the Department of Chemistry, Princeton University, Princeton, NJ (J.T.G.); and the Experimental Research Department and Institute of Human Physiology, Semmelweis University Medical School, Budapest, Hungary (C.S.).
Correspondence to Csaba Szabó, MD, PhD, DSc, Inotek Pharmaceuticals Corporation, Suite 419E, 100 Cummings Center, Beverly, MA 01915. E-mail szabocsaba{at}aol.com
Background— Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction.
Methods and Results— Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance. In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity.
Conclusions— Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.
Key Words: cardiac function • doxorubicin • oxidative stress • nitric oxide • heart failure
This article has been cited by other articles:
 |
|
 |
|
  P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1466 - H1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pan, P. Mukhopadhyay, M. Rajesh, V. Patel, B. Mukhopadhyay, B. Gao, G. Hasko, and P. Pacher Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Riad, S. Bien, D. Westermann, P. M. Becher, K. Loya, U. Landmesser, H. K. Kroemer, H. P. Schultheiss, and C. Tschope Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice Cancer Res., January 15, 2009; 69(2): 695 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al. The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy Cancer Res., November 1, 2007; 67(21): 10428 - 10435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Batkai, P. Mukhopadhyay, J. Harvey-White, R. Kechrid, P. Pacher, and G. Kunos Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1689 - H1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N. P. Gerard, L. Liaudet, G. Kunos, et al. Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity J. Am. Coll. Cardiol., August 7, 2007; 50(6): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, X. Zhang, B. Qian, X. Min, X. Gao, C. Li, Y. Cheng, and J. Huang Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice Eur J Heart Fail, August 1, 2007; 9(8): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Deng, J.-P. Huang, L.-S. Lu, and L.-M. Hung Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H978 - H987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Batkai, M. Rajesh, P. Mukhopadhyay, G. Hasko, L. Liaudet, B. F. Cravatt, A. Csiszar, Z. Ungvari, and P. Pacher Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H909 - H918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Neilan, S. L. Blake, F. Ichinose, M. J. Raher, E. S. Buys, D. S. Jassal, E. Furutani, T. M. Perez-Sanz, A. Graveline, S. P. Janssens, et al. Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin Circulation, July 31, 2007; 116(5): 506 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Buys, M. J. Raher, S. L. Blake, T. G. Neilan, A. R. Graveline, J. J. Passeri, M. Llano, T. M. Perez-Sanz, F. Ichinose, S. Janssens, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H620 - H627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Christiansen and R. Autschbach Doxorubicin in experimental and clinical heart failure. Eur. J. Cardiothorac. Surg., October 1, 2006; 30(4): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Levrand, B. Pesse, F. Feihl, B. Waeber, P. Pacher, J. Rolli, M.-D. Schaller, and L. Liaudet Peroxynitrite Is a Potent Inhibitor of NF-{kappa}B Activation Triggered by Inflammatory Stimuli in Cardiac and Endothelial Cell Lines J. Biol. Chem., October 14, 2005; 280(41): 34878 - 34887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chicco, C. M. Schneider, and R. Hayward Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R424 - R431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, J. Liu, J. Harvey-White, A. Brassai, Z. Jarai, B. F. Cravatt, and G. Kunos Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H533 - H541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Pieper, V. Nilakantan, M. Chen, J. Zhou, A. K. Khanna, J. D. Henderson Jr., C. P. Johnson, A. M. Roza, and C. Szabo Protective Mechanisms of a Metalloporphyrinic Peroxynitrite Decomposition Catalyst, WW85, in Rat Cardiac Transplants J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE Mol. Interv., June 1, 2005; 5(3): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Xiao, M. Chen, Z. Zsengeller, H. Li, L. Kiss, M. Kollai, and C. Szabo Poly(ADP-Ribose) Polymerase Promotes Cardiac Remodeling, Contractile Failure, and Translocation of Apoptosis-Inducing Factor in a Murine Experimental Model of Aortic Banding and Heart Failure J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 891 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, A. Vaslin, R. Benko, J. G. Mabley, L. Liaudet, G. Hasko, A. Marton, S. Batkai, M. Kollai, and C. Szabo A New, Potent Poly(ADP-ribose) Polymerase Inhibitor Improves Cardiac and Vascular Dysfunction Associated with Advanced Aging J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, J. G. Mabley, L. Liaudet, O. V. Evgenov, A. Marton, G. Hasko, M. Kollai, and C. Szabo Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2132 - H2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M. A. Rudd, R. D. Bukoski, et al. Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension Circulation, October 5, 2004; 110(14): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szabo and C. Szabo Reply to the Editor J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 324 - 325. [Full Text] [PDF]
|
|
|
|
|
|
S. Batkai, P. Pacher, Z. Jarai, J. A. Wagner, and G. Kunos Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H595 - H600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice J. Physiol., July 15, 2004; 558(2): 647 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Radi Nitric oxide, oxidants, and protein tyrosine nitration PNAS, March 23, 2004; 101(12): 4003 - 4008. [Abstract] [Full Text] [PDF]
|
|